+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neurofibromatosis Type - 2 - Market Insights, Epidemiology, and Market Forecast - 2030

  • ID: 5292798
  • Drug Pipelines
  • January 2021
  • Region: Global
  • 200 pages
  • DelveInsight

FEATURED COMPANIES

  • AstraZeneca
  • Genentech
  • Novartis
  • Pfizer
  • Recursion Pharmaceuticals
  • Takeda
This ‘Neurofibromatosis Type-2 (NF2)- Market Insights, Epidemiology, and Market Forecast - 2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Neurofibromatosis Type-2 (NF2) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China.

The Neurofibromatosis Type-2 market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Neurofibromatosis Type-2 market Size from 2017 to 2030, segmented by G-8 major markets. The report also covers the current Neurofibromatosis Type-2 treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • China
Study Period:
2017-2030

Neurofibromatosis Type-2: Disease Understanding and Treatment Algorithm

Neurofibromatosis Type-2 Overview

Neurofibromatosis type 2 (NF2) is a rare genetic autosomal dominant, neurological, and neurodegenerative, tumor predisposition condition that results in slow-growing typically benign tumors, primarily located in the central nerve system (CNS); brain, and spinal cord. Clinical NF2 follows a genetic alteration to the NF2 gene, which disrupts the function of a cell membrane-related protein, merlin. Though the role of merlin is incompletely understood, it acts as tumor-suppressive by affecting multiple signaling pathways important for contact inhibition, cellular proliferation, and cellular growth.

The NF2 has a bimodal age of onset in children and young adults, with the former tending to present as severe phenotype with multiple tumors. Correspondingly, the clinical presentation of NF2 is grouped into two main subtypes: the more aggressive Wishart type¬¬¬-common for childhood-onset, and the less aggressive Gardner type-presenting in adulthood.

NF2 may lead to the most common clinical manifestations include bilateral vestibular schwannoma (VS), intracranial, and spinal tumors (schwannomas, meningiomas, and ependymomas), peripheral neuropathy, cataracts, and cutaneous tumors. Adults tend to present with symptoms of tinnitus, hearing loss, and/or imbalance related to VS, while children have symptoms due to spinal cord compression or other CNS-tumors, as well as ophthalmologic involvement.

The diagnosis is made based on the presence of specific clinical features. Under the NIH diagnostic criteria, a patient can be diagnosed with NF2 if they have bilateral VS or have a family history significant for NF2 and any one of the following: unilateral VS, another schwannoma, meningioma, glioma, neurofibroma, or juvenile posterior subscapular lens opacity. Refinements to the diagnostic criteria of NF2 have been proposed over time due to increasing understanding of clinical and molecular data. Large-population studies have demonstrated that some features, such as the development of gliomas and neurofibromas, currently included as diagnostic criteria, may require further clarification and modification.

Multidisciplinary management is required in patients with NF2, including oncologists, neurologists, neuroradiologists, ophthalmologists, geneticists, and neurosurgeons. For tumor surveillance, an annual brain MRI is recommended. Small asymptomatic vestibular schwannomas can be managed conservatively with MRI follow-up. Surgery is the primary treatment for large symptomatic vestibular schwannomas. Meningiomas are also treated surgically with radiation treatment reserved for non-surgical candidates. The spinal cord ependymomas are usually low-grade tumors and can be followed clinically with surgery reserved for symptomatic patients. Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is new systemic immunotherapy for a wide range of tumors. Multiple studies have shown tumor regression and hearing improvement in NF2 patients treated with bevacizumab.

Neurofibromatosis Type-2 Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Neurofibromatosis Type-2 market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, Japan, and China.

The Neurofibromatosis Type-2 market report gives a thorough understanding of Neurofibromatosis Type-2 by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Neurofibromatosis Type-2 in the US, Europe, Japan, and China.

Neurofibromatosis Type-2 Epidemiology

The Neurofibromatosis Type-2 epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every G-8 major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Neurofibromatosis Type-2 epidemiology segmented as the total diagnosed prevalent cases of Neurofibromatosis Type-2, age-specific cases of Neurofibromatosis Type-2, and tumor-specific cases of Neurofibromatosis Type-2. The report includes the prevalent scenario of Neurofibromatosis Type-2 symptoms in the G-8 covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2017 to 2030.

Country-wise Neurofibromatosis Type-2 Epidemiology

The epidemiology segment also provides the Neurofibromatosis Type-2 epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.

The total diagnosed prevalence population of Neurofibromatosis Type-2 in the G-8 countries were 59,274 cases in 2020.

Neurofibromatosis Type-2 Drug Chapters

The drug chapter segment of the Neurofibromatosis Type-2 report encloses the detailed analysis of Neurofibromatosis Type-2 marketed drugs and late stage (Phase-II and Phase-I/II) pipeline drugs. It also helps to understand the Neurofibromatosis Type-2 clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Currently, available treatments are non-curative. Despite the high morbidity associated with NF2 in severe cases, management of NF2-associated lesions primarily consists of surgical resection and treatment of symptoms.

Surgery can be used to remove most tumors, although it carries a risk of causing problems, such as complete deafness or facial weakness. Therefore, the risks and potential benefits need to be carefully considered before treatment. Small asymptomatic vestibular schwannomas can be managed conservatively with MRI follow-up. Surgery is the primary treatment for large symptomatic vestibular schwannomas. Also, localized radiation therapy is sometimes used for vestibular schwannomas, however, may risk the person’s hearing capacity as like surgery. Most people with NF2 eventually develop significant hearing loss and often benefit from using a hearing aid or learning to lip read. Special implants can sometimes be inserted to improve a person’s hearing. NF2 tends to get worse over time, although the speed at which this happens varies considerably.

Bevacizumab (Genentech) is a VEGF inhibitor, which prevents the interaction of VEGF to its receptors (Flt-1 and KDR) and inhibits cell proliferation and new blood vessels. Intravenous chemotherapy with Bevacizumab has been introduced in the last decade as one of the treatment options for NF2 patients. It is recommended for patients who have evidence of tumor progression and are considered poor candidates for surgery and radiotherapy. The drug has shown tumor shrinkage and hearing improvement. Following that, several studies reported the influence of Bevacizumab to decrease tumor volume and improve the hearing response in NF2 patients. Although the existing evidence supporting the use of Bevacizumab as a medical therapy is not stronger than level 3, the drug is in the extensive usage throughout the G-8 countries.

Neurofibromatosis Type-2 Emerging Drugs

The MEK inhibitor¬-Selumetinib (AstraZeneca) regulate the extracellular signal-related kinase (ERK) pathway. This is the first-ever therapy to approved neurofibromatosis type 1 in the US and planning to enter the EU market. As per AstraZeneca, the drug has the potential to be expanded to all the neurofibromatosis types. Currently, the company is conducting phase II clinical studies for evaluating Selumetinib in patients with neurofibromatosis type 2 related tumors. By considering all these factors, the drug is expected to reach the US market by 2025 and drive future generation researches.

The mTOR inhibitor- Everolimus (Novartis) is already available in the market for multiple cancer indications and conducted clinical studies with progressive VS in NF2 patients. Even though, the trail did not meet the primary endpoint, evidence suggesting the potential to stabilize or delay tumor growth. To confirm the same, another phase II trial is evaluating the Everolimus as monotherapy in the treatment of Neurofibromatosis Type 2 - related vestibular schwannoma. The positive results from this trial may help the drug to reach the market by 20XX.

Neurofibromatosis Type-2 Market Outlook

The Neurofibromatosis Type-2 market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Neurofibromatosis Type-2 market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Neurofibromatosis Type-2 market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the Neurofibromatosis Type-2 market in the G-8 is expected to change in the study period 2017-2030.

Increased understanding of the clinical manifestations of neurofibromatosis type 2 in conjunction with improved precision of genetic tests and imaging studies has improved the early diagnosis of patients. Further insight into the molecular pathogenesis and natural history of lesions along with advances in treatment and restorative modalities, will lead to improved management as well as advancements in clinical therapeutics

Key Findings

This section includes a glimpse of the Neurofibromatosis Type-2 market in the G-8. The market size of Neurofibromatosis Type-2 in the G-8 was found to be USD 188.09 Million in 2020.

The United States: Market Outlook

This section provides the total Neurofibromatosis Type-2 market size and market size by therapies of Neurofibromatosis Type-2 in the United States.

The United States accounts for the highest market size of Neurofibromatosis Type-2 in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), Japan, and China.

Surgical resection is the mainstay for growing tumors but comes at the cost of significant morbidity, while radiotherapy is generally not advisable due to the risk of secondary malignancy and malignant transformation. Hence, there remains a critical demand for effective anti-neoplastic therapies for NF2-related tumors.

There is a lack of systemic therapies that address the underlying biology of the syndrome. Since NF2-related tumors tend to be slow-growing, options such as cytotoxic chemotherapies are not appropriate to treat this lifelong condition. Thus, molecularly targeted therapies represent a better treatment modality and a budding and encouraging prospect.

At present, international studies have found that some drugs can effectively control or even reduce the size of tumors. At present, the world has begun to use drugs to treat NF2 tumors. Reduce tumor volume and control tumor growth through oral or intravenous injection of drugs has been observed with the use of Bevacizumab.

EU-5 Countries: Market Outlook

The total Neurofibromatosis Type-2 market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.

Japan Market Outlook

The total Neurofibromatosis Type-2 market size and market size by therapies of Neurofibromatosis Type-2 in Japan are also mentioned.

China Market Outlook

The total Neurofibromatosis Type-2 market size and market size by therapies of Neurofibromatosis Type-2 in China are also mentioned.

Neurofibromatosis Type-2 Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Neurofibromatosis Type-2 market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Neurofibromatosis Type-2 Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase I/II stage. It also analyses Neurofibromatosis Type-2 key players involved in developing targeted therapeutics.

Major players include Selumetinib (AstraZeneca), Bevacizumab (Genentech), Axitinib (Pfizer), Brigatinib (Takeda), AZD2014 (AstraZeneca), Everolimus (Novartis), AR-42/ REC-2282 (Recursion Pharmaceuticals), and others. The key products are expected to get launched in the US market by 20XX.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Neurofibromatosis Type-2 emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the Neurofibromatosis Type-2 domain through primary research to fill the data gaps and validate the secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Neurofibromatosis Type-2 market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs a Competitive and Market Intelligence analysis of the Neurofibromatosis Type-2 market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Neurofibromatosis Type-2, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Neurofibromatosis Type-2 epidemiology and treatment in the G-8.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Neurofibromatosis Type-2 is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Neurofibromatosis Type-2 market; historical and forecasted, is included in the report, covering drug outreach in the G-8
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Neurofibromatosis Type-2 market
Report Highlights
  • In the coming years, the Neurofibromatosis Type-2 market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Neurofibromatosis Type-2 R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Neurofibromatosis Type-2. The launch of emerging therapies will significantly impact the Neurofibromatosis Type-2 market
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Neurofibromatosis Type-2.
  • the in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Neurofibromatosis Type-2 Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Neurofibromatosis Type-2 Pipeline Analysis
  • Neurofibromatosis Type-2 Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Neurofibromatosis Type-2 Report Key Strengths
  • 11-years Forecast
  • G-8 Coverage
  • Neurofibromatosis Type-2 Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake
Neurofibromatosis Type-2 Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions Answered

Market Insights:
  • What was the Neurofibromatosis Type-2 Market share (%) distribution in 2017, and how would it look like in 2030?
  • What would be the Neurofibromatosis Type-2 total market Size and market Size by therapies across the G-8 during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across G-8, and which country will have the largest Neurofibromatosis Type-2 market Size during the forecast period (2017-2030)?
  • At what CAGR, the Neurofibromatosis Type-2 market is expected to grow in the G-8 during the forecast period (2017-2030)?
  • What would be the Neurofibromatosis Type-2 market outlook across the G-8 during the forecast period (2017-2030)?
  • What would be the Neurofibromatosis Type-2 market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
  • What are the disease risk, burden, and unmet needs of the Neurofibromatosis Type-2?
  • What is the historical Neurofibromatosis Type-2 patient pool in G-8 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China?
  • What would be the forecasted patient pool of Neurofibromatosis Type-2 in G-8 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China?
  • What will be the growth opportunities in the G-8 with respect to the patient population pertaining to Neurofibromatosis Type-2?
  • Out of all G-8 countries, which country would have the highest prevalent population of Neurofibromatosis Type-2 during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in the G-8 during the forecast period (2017-2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
  • What are the current options for the treatment of Neurofibromatosis Type-2?
  • What are the current treatment guidelines for treating Neurofibromatosis Type-2 in the USA, Europe, Japan, and China?
  • What are the Neurofibromatosis Type-2 marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Neurofibromatosis Type-2?
  • How many therapies are developed by each company for the treatment of Neurofibromatosis Type-2?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Neurofibromatosis Type-2?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Neurofibromatosis Type-2 therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Neurofibromatosis Type-2 and their status?
  • What are the key designations that have been granted for the emerging therapies for Neurofibromatosis Type-2?
  • What are the global historical and forecasted market for Neurofibromatosis Type-2?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Neurofibromatosis Type-2 market
  • To understand the future market competition in the Neurofibromatosis Type-2 market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Neurofibromatosis Type-2 in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), Japan, and China.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Neurofibromatosis Type-2 market.
  • To understand the future market competition in the Neurofibromatosis Type-2 market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca
  • Genentech
  • Novartis
  • Pfizer
  • Recursion Pharmaceuticals
  • Takeda
1. Key Insights

2. Neurofibromatosis Type-2: Market Overview at a Glance
2.1. Market Share (%) Distribution of Neurofibromatosis Type-2 in 2017
2.2. Market Share (%) Distribution of Neurofibromatosis Type-2 in 2030

3. Organizations

4. Executive Summary

5. Disease Overview: Neurofibromatosis Type-2
5.1. Clinical forms of Neurofibromatosis Type-2
5.2. Clinical Manifestations
5.3. Neoplastic manifestations of neurofibromatosis type 2
5.4. Pathogenesis
5.5. Diagnosis
5.6. Differential diagnosis

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Total Diagnosed prevalent cases of NF2 in G-8 Countries
6.3. Assumptions and Rationale
6.4. The United States
6.4.1. Total Diagnosed Prevalence of NF2 in the United States
6.4.2. Age-Specific Cases of NF2 in the United States
6.4.3. Tumor-Specific Cases of NF2 in the United States
6.5. Germany
6.5.1. Total Diagnosed Prevalence of NF2 in Germany
6.5.2. Age-Specific Cases of NF2 in Germany
6.5.3. Tumor-Specific Cases of NF2 in Germany
6.6. France
6.6.1. Total Diagnosed Prevalence of NF2 in France
6.6.2. Age-Specific Cases of NF2 in France
6.6.3. Tumor-Specific Cases of NF2 in France
6.7. Italy
6.7.1. Total Diagnosed Prevalence of NF2 in Italy
6.7.2. Age-Specific Cases of NF2 in Italy
6.7.3. Tumor-Specific Cases of NF2 in Italy
6.8. Spain
6.8.1. Total Diagnosed Prevalence of NF2 in Spain
6.8.2. Age-Specific Cases of NF2 in Spain
6.8.3. Tumor-Specific Cases of NF2 in Spain
6.9. The UK
6.9.1. Total Diagnosed Prevalence of NF2 in the UK
6.9.2. Age-Specific Cases of NF2 in the UK
6.9.3. Tumor-Specific Cases of NF2 in the UK
6.10. Japan
6.10.1. Total Diagnosed Prevalence of NF2 in Japan
6.10.2. Age-Specific Cases of NF2 in Japan
6.10.3. Tumor-Specific Cases of NF2 in Japan
6.11. China
6.11.1. Total Diagnosed Prevalence of NF2 in China
6.11.2. Age-Specific Cases of NF2 in China
6.11.3. Tumor-Specific Cases of NF2 in China

7. Treatment and Management

8. Unmet Needs

9. Emerging Therapies
9.1. Key cross competition
9.2. Selumetinib: AstraZeneca
9.2.1. Drug Description
9.2.2. Other Development Activities
9.2.3. Clinical Development
9.2.4. Product Profile
9.3. AZD2014: AstraZeneca
9.3.1. Drug Description
9.3.2. Clinical Development
9.3.3. Product Profile
9.4. Everolimus: Novartis
9.4.1. Drug Description
9.4.2. Clinical Development
9.4.3. Safety and Efficacy
9.4.4. Product Profile
9.5. Bevacizumab: Genentech
9.5.1. Drug Description
9.5.2. Clinical Development
9.5.3. Safety and Efficacy
9.5.4. Product Profile
9.6. Other Emerging Therapies
9.7. Brigatinib: Takeda
9.7.1. Clinical Development
9.7.2. Clinical Development
9.7.3. Product Profile
9.8. REC-2282: Recursion Pharmaceuticals
9.8.1. Product Description
9.8.2. Other Developmental Activities
9.8.3. Clinical Development
9.8.4. Safety and Efficacy
9.8.5. Product Profile
9.9. Axitinib: Pfizer
9.9.1. Drug Description
9.9.2. Other Development Activities
9.9.3. Clinical Development
9.9.4. Product Profile

10. Neurofibromatosis 2 (NF2): 7 Major Market Analysis
10.1. Key Findings
10.2. Market Size of NF2 in G-8 Countries

11. Market Outlook
11.1. The United States Market Size
11.1.1. The Total Market Size of NF2 in the United States
11.1.2. The Market Size of NF2 by therapies in the United States
11.2. Germany Market Size
11.2.1. The Total Market Size of NF2 in Germany
11.2.2. The Market Size of NF2 by therapies in Germany
11.3. France Market Size
11.3.1. The Total Market Size of NF2 in France
11.3.2. The Market Size of NF2 by therapies in France
11.4. Italy Market Size
11.4.1. The Total Market Size of NF2 in Italy
11.4.2. The Market Size of NF2 by therapies in Italy
11.5. Spain Market Size
11.5.1. The Total Market Size of NF2 in Spain
11.5.2. The Market Size of NF2 by therapies in Spain
11.6. The UK Market Size
11.6.1. The Total Market Size of NF2 in the UK
11.6.2. The Market Size of NF2 by therapies in The UK
11.7. Japan Market Size
11.7.1. The Total Market Size of NF2 in Japan
11.7.2. The Market Size of NF2 by therapies in Japan
11.8. China Market Size
11.8.1. The Total Market Size of NF2 in China
11.8.2. The Market Size of NF2 by therapies in China

12. Market Drivers

13. Market Barriers

14. Market Access

15. SWOT Analysis

16. Case Studies
16.1. Neurofibromatosis type 2 initially presenting as a preauricular mass: a case report
16.2. Ocular Findings of Neurofibromatosis 2: A Case Study
16.3. Renal vascular disease in neurofibromatosis type 2: association or coincidence?
16.4. Brainstem ischemic syndrome in juvenile NF2

17. KOL Views

18. Bibliography

19. Appendix

20. Report Methodology

21. Publisher Capabilities

22. Disclaimer

23. About the Publisher

List of Tables
Table 1: Clinical features associated with Neurofibromatosis Type 2
Table 2: Mutations in the NF2 gene
Table 3: NIH criteria (1987) and NIH criteria (1991)
Table 4: Manchester (NIH) Criteria (1992) for neurofibromatosis type II
Table 5: NF2 Baser Pediatric Diagnostic Criteria (2016 - December 2018)
Table 6: Manchester Criteria (1997 - 2016)
Table 7: Recommended Follow-Up for Children at Risk of Having NF2
Table 8: Disorders to Consider in the Differential Diagnosis of NF2
Table 9: Total Diagnosed prevalence in G-8 Countries (2017-2030)
Table 10: Total Diagnosed prevalence of NF2 in the US (2017-2030)
Table 11: Age-Specific Cases of NF2 in the US (2017-2030)
Table 12: Tumor-Specific Cases of NF2 in the US (2017-2030)
Table 13: Total Diagnosed prevalence of NF2 in Germany (2017-2030)
Table 14: Age-Specific Cases of NF2 in Germany (2017-2030)
Table 15: Tumor-Specific Cases of NF2 in Germany (2017-2030)
Table 16: Total Diagnosed prevalence of NF2 in France (2017-2030)
Table 17: Age-Specific Cases of NF2 in France (2017-2030)
Table 18: Tumor-Specific Cases of NF2 in France (2017-2030)
Table 19: Total Diagnosed prevalence of NF2 in Italy (2017-2030)
Table 20: Age-Specific Cases of NF2 in Italy (2017-2030)
Table 21: Tumor-Specific Cases of NF2 in Italy (2017-2030)
Table 22: Total Diagnosed prevalence of NF2 in Spain (2017-2030)
Table 23: Age-Specific Cases of NF2 in Spain (2017-2030)
Table 24: Tumor-Specific Cases of NF2 in Spain (2017-2030)
Table 25: Total Diagnosed prevalence of NF2 in the UK (2017-2030)
Table 26: Age-Specific Cases of NF2 in the UK (2017-2030)
Table 27: Tumor-Specific Cases of NF2 in the UK (2017-2030)
Table 28: Total Diagnosed prevalence of NF2 in Japan (2017-2030)
Table 29: Age-Specific Cases of NF2 in Japan (2017-2030)
Table 30: Tumor-Specific Cases of NF2 in Japan (2017-2030)
Table 31: Total Diagnosed prevalence of NF2 in China (2017-2030)
Table 32: Age-Specific Cases of NF2 in China (2017-2030)
Table 33: Tumor-Specific Cases of NF2 in China (2017-2030)
Table 34: Key cross of the emerging drugs
Table 35: Selumetinib, Clinical Trial Description, 2020
Table 36: AZD2014, Clinical Trial Description, 2020
Table 37: Everolimus, Clinical Trial Description, 2020
Table 38: Bevacizumab, Clinical Trial Description, 2020
Table 39: Brigatinib., Clinical Trial Description, 2020
Table 40: REC-2282, Clinical Trial Description, 2020
Table 41: Axitinib, Clinical Trial Description, 2020
Table 42: Market Size of NF2 in G-8 Countries in USD Million (2017-2030)
Table 43: Market Size of NF2 in the US in USD Million (2017-2030)
Table 44: Market Size of NF2 by therapies in the US in USD Million (2017-2030)
Table 45: Market Size of NF2 in Germany in USD Million (2017-2030)
Table 46: Market Size of NF2 by therapies in Germany in USD Million (2017-2030)
Table 47: Market Size of NF2 in France in USD Million (2017-2030)
Table 48: Market Size of NF2 by therapies in France in USD Million (2017-2030)
Table 49: Market Size of NF2 in Italy in USD Million (2017-2030)
Table 50: Market Size of NF2 by therapies in Italy in USD Million (2017-2030)
Table 51: Market Size of NF2 in Spain in USD Million (2017-2030)
Table 52: Market Size of NF2 by therapies in Spain in USD Million (2017-2030)
Table 53: Market Size of NF2 in the UK in USD Million (2017-2030)
Table 54: Market Size of NF2 by therapies in the UK in USD Million (2017-2030)
Table 55: Market Size of NF2 in Japan in USD Million (2017-2030)
Table 56: Market Size of NF2 by therapies in Japan in USD Million (2017-2030)
Table 57: Market Size of NF2 in China in USD Million (2017-2030)
Table 58: Market Size of NF2 by therapies in China in USD Million (2017-2030)

List of Figures
Figure 1: Clinical forms of NF-2
Figure 2: Clinical Manifestations associated with NF2
Figure 3: Neoplastic manifestations of neurofibromatosis type 2
Figure 4: Molecular biology of Merlin
Figure 5: Total Diagnosed prevalence in G-8 Countries (2017-2030)
Figure 6: Total Diagnosed prevalence of NF2 in the US (2017-2030)
Figure 7: Age-Specific Cases of NF2 in the US (2017-2030)
Figure 8 Tumor-Specific Cases of NF2 in the US (2017-2030)
Figure 9: Total Diagnosed prevalence of NF2 in Germany (2017-2030)
Figure 10: Age-Specific Cases of NF2 in Germany (2017-2030)
Figure 11: Tumor-Specific Cases of NF2 in Germany (2017-2030)
Figure 12: Total Diagnosed prevalence of NF2 in France (2017-2030)
Figure 13: Age-Specific Cases of NF2 in France (2017-2030)
Figure 14 Tumor-Specific Cases of NF2 in France (2017-2030)
Figure 15: Total Diagnosed prevalence of NF2 in Italy (2017-2030)
Figure 16: Age-Specific Cases of NF2 in Italy (2017-2030)
Figure 17: Tumor-Specific Cases of NF2 in Italy (2017-2030)
Figure 18: Total Diagnosed prevalence of NF2 in Spain (2017-2030)
Figure 19: Age-Specific Cases of NF2 in Spain (2017-2030)
Figure 20: Tumor-Specific Cases of NF2 in Spain (2017-2030)
Figure 21: Total Diagnosed prevalence of NF2 in the UK (2017-2030)
Figure 22: Age-Specific Cases of NF2 in the UK (2017-2030)
Figure 23:Tumor-Specific Cases of NF2 in the UK (2017-2030)
Figure 24: Total Diagnosed prevalence of NF2 in Japan (2017-2030)
Figure 25: Age-Specific Cases of NF2 in Japan (2017-2030)
Figure 26: Tumor-Specific Cases of NF2 in Japan (2017-2030)
Figure 27: Total Diagnosed prevalence of NF2 in China (2017-2030)
Figure 28: Age-Specific Cases of NF2 in China (2017-2030)
Figure 29: Tumor-Specific Cases of NF2 in China (2017-2030)
Figure 30: Decision points in the clinical management of NF2 associated vestibular schwannomas.
Figure 31: Unmet Needs
Figure 32: Market Size of NF2 in USD Million (2017-2030)
Figure 33: Market Size of NF2 in the US in USD Millions (2017-2030)
Figure 34: Market Size of NF2 by therapies in the US, USD Millions (2017-2030)
Figure 35: Market Size of NF2 in Germany in USD Millions (2017-2030)
Figure 36: Market Size of NF2 by therapies in Germany, USD Millions (2017-2030)
Figure 37: Market Size of NF2 in France in USD Millions (2017-2030)
Figure 38: Market Size of NF2 by therapies in France, USD Millions (2017-2030)
Figure 39: Market Size of NF2 in Italy in USD Millions (2017-2030)
Figure 40: Market Size of NF2 by therapies in Italy, USD Millions (2017-2030)
Figure 41: Market Size of NF2 in Spain in USD Millions (2017-2030)
Figure 42: Market Size of NF2 by therapies in Spain, USD Millions (2017-2030)
Figure 43: Market Size of NF2 in the UK in USD Millions (2017-2030)
Figure 44: Market Size of NF2 by therapies in the UK, USD Millions (2017-2030)
Figure 45: Market Size of NF2 in Japan in USD Millions (2017-2030)
Figure 46: Market Size of NF2 by therapies in Japan, USD Millions (2017-2030)
Figure 47: Market Size of NF2 in China in USD Millions (2017-2030)
Figure 48: Market Size of NF2 by therapies in China, USD Millions (2017-2030)
Figure 49: Market Drivers
Figure 50: Market Barriers
Note: Product cover images may vary from those shown
  • AstraZeneca
  • Novartis
  • Genentech
  • Takeda
  • Recursion Pharmaceuticals
  • Pfizer
Note: Product cover images may vary from those shown
Adroll
adroll